학술논문
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
Document Type
journal article
Author
Source
Journal of Clinical Oncology; 8/10/2009, Vol. 27 Issue 23, p3742-3748, 7p
Subject
Language
ISSN
0732183X